Gennex Laboratories FY26: ₹173 Crore of Sales, and ₹64 Crore That Walked Out the Operating Door
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1 — At a Glance
Gennex Laboratories closed FY26 with revenue of ₹172.74 crore, up 25.3% from ₹137.9 crore — the third straight year of double-digit top-line growth. Net profit attributable to owners, however, landed at ₹18.46 crore against ₹18.12 crore the year before: a 1.9% move. Sales sprinted; profit walked.
The line that does the most work sits in the cash flow statement. Operating activities consumed ₹63.65 crore during the year — cash flowing the wrong way while the P&L reported a profit. The gap was financed: borrowings climbed from ₹10.22 crore to ₹79.36 crore, and a fresh capital issue added ₹17.2 crore.
The balance sheet grew from ₹256 crore to ₹349 crore in twelve months. Receivables tripled, inventory rose by half, and a promoter pledge surfaced in June. The auditor signed a Qualified Opinion — the repetitive kind.
A profit on the statement and a hole in the cash account can coexist for a while. How long that while runs is the question the rest of this entry circles.
The market caps the company at ₹260 crore. What that figure is paying for comes later.
2 — Introduction
Incorporated in 1995, Gennex Laboratories manufactures bulk drugs and intermediates — Active Pharmaceutical Ingredients — from a production unit in Hyderabad. It is a vertically integrated maker and exporter of APIs, intermediates and biotech products: expectorants, muscle relaxants, analgesics and antifungals among them.
The recent corporate history is one of capital expansion. On December 4, 2023 the board approved raising authorised capital from ₹20 crore to ₹25 crore, issuing up to 1.55 crore warrants to promoters on a preferential basis, and a rights issue. Through FY26 those warrants converted: equity share capital rose from ₹22.74 crore to ₹24.29 crore, and the financing line records ₹17.2 crore of capital proceeds.
The board met on May 30, 2026 to approve audited standalone and consolidated results for the quarter and year ended March 31, 2026. Those results carried a qualification from the statutory auditor, R Pugalia & Company, concerning unconfirmed balances — an item flagged as repetitive.
The company reports a single operating segment: Bulk Drugs, Biotech Products and Intermediates. It has one subsidiary, Deccan Remedies Limited, which received a test licence from the Andhra Pradesh Drugs Control Administration in October 2024.
Figures throughout are consolidated, in ₹ crore, unless stated.
3 — Business Model: WTF Do They Even Do?
Gennex makes the molecules other companies put inside pills. The product list reads like a pharmacist’s drawer: Guaifenesin (an expectorant), Methocarbamol (a skeletal muscle relaxant), Fexofenadine (an antihistamine), Fluconazole (an antifungal), Sertraline (an SSRI), Allopurinol, and a handful more. It does not sell to your chemist; it sells to the people who sell to your chemist.
The model is a single-segment API maker — management itself says so, identifying just one reportable segment. There is no consumer brand here doing quiet compounding, no patent moat with a countdown clock. There is a plant in Hyderabad with an installed capacity of 85+ KL, a stack of ISO and WHO-GMP certificates, and a customer base that wants kilograms of consistent chemistry at a competitive price.
Geography is the genuinely interesting part. The FY26 standalone segment disclosure puts India at ₹84.02 crore of ₹119.86 crore — about 70% domestic. The rest is export, spread across an atlas: Vietnam (₹13.47 crore), Colombia (₹9.17 crore), Egypt (₹3.68 crore), plus Peru, Mexico, Guatemala, Spain and a long tail of countries each contributing a rounding error. A muscle relaxant intermediate shipped to El Salvador is a fact the data sheet records without blinking.
The trouble with being a vertically integrated commodity API maker is that raw material consumed scales almost in lockstep with sales. Cost of material consumed ran ₹139.62 crore on ₹172.74 crore of sales in FY26 — roughly 81 paise of every sales rupee, before a single other cost. Operating margin held at 13%. This is a business model that converts chemistry into revenue efficiently and revenue into profit only modestly. The value-add is real, but it is thin, and it is priced by buyers who can count.
Does a 70%-domestic, single-segment API book earn the premium of a diversified pharma franchise, or is it a tolling operation with an export brochure? The numbers below lean toward the second.
